The global peripheral neuropathy treatment market is estimated to grow at a CAGR of 4.3% during the forecast period. The increasing prevalence of diabetes and cancer and rising launches of generic versions of peripheral neuropathy drugs are some pivotal factors accelerating market growth. As per the International Diabetes Federation (IDF), in 2019, nearly 463 million adults (20-79 years) were suffering from diabetes, which is expected to reach 700 million by 2045. The most common diabetic complication is peripheral neuropathy. It is a severe diabetic complication that may affect nearly 50% of people suffering from diabetes. This condition affects the legs and feet first and is followed by hands and arms.
To Request a Sample of our Report on Global Peripheral Neuropathy Treatment Market: https://www.omrglobal.com/request-sample/peripheral-neuropathy-treatment-market
Several prescription medications are available for diabetes-associated nerve pain. Some antidepressants provide ease to nerve pain. Tricyclic antidepressants may support mild to moderate nerve pain. This class of drugs includes imipramine (Tofranil), amitriptyline, and desipramine (Norpramin). With the increasing prevalence of diabetic neuropathy, some new launches of generic peripheral neuropathy drugs have been reported over the years. For instance, in July 2019, Rising Pharmaceuticals, Inc. declared the US launch of a generic version of Lyrica (pregabalin) capsules. These are available in eight commercially available strengths (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, & 300 mg).
Pregabalin capsules are designated for the treatment of neuropathic pain related to diabetic peripheral neuropathy, for the neuropathic pain management associated with spinal cord injury, for the management of fibromyalgia, for postherpetic neuralgia management, and for adjunctive therapy to treat partial-onset seizures in patients 4 years of age and older. The launch of generic drugs is offering a cost-effective treatment alternative for patients suffering from debilitating neuropathic pain conditions. This, in turn, will provide growth opportunities for the market.
A full Report of Global Peripheral Neuropathy Treatment Market is Available @ https://www.omrglobal.com/industry-reports/peripheral-neuropathy-treatment-market
Global Peripheral Neuropathy Treatment Market-Segmentation
By Type
- Antidepressants
- Pain Relievers
- Antiseizure
- Others
By Application
- Diabetes
- Chemotherapy-Induced
- Others
Regional Analysis
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Company Profiles
- Achelios Therapeutics, Inc.
- Acorda Therapeutics, Inc.
- Alembic Pharmaceuticals, Ltd.
- Amneal Pharmaceuticals LLC
- Apotex, Inc.
- Assertio Therapeutics, Inc.
- Bristol Myers Squibb Co.
- Cipla, Ltd.
- Daiichi Sankyo Company, Ltd.
- Eli Lilly and Co.
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals, Ltd.
- Grünenthal GmbH
- Innovus Pharmaceuticals, Inc.
- Johnson & Johnson Services, Inc.
- Lupin, Ltd.
- Mylan N.V.
- Novartis International AG
- Pfizer, Inc.
- Teva Pharmaceutical Industries, Ltd.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/peripheral-neuropathy-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
